Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14284 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Alexander Slowley und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Value, Evidence and Outcomes Europe, London, UK. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Anemia. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
Objectives
There is limited data on the incidence, prevalence, and treatments for myelofibrosis (MF) in Germany. This retrospective study examined claims data from 3.3 million insured individuals, spanning from 2010 to 2021.
Methods
Four sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross‐sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and/or splenomegaly, including first‐line (1L) Janus kinase inhibitor (JAKi), second‐line, or further (2L+) MF‐related treatment therapies during 2021. The prevalence of anemia treatment was also reported.
Results
The estimated standardized point prevalence of MF on December 31, 2021, was 9.9–12.4 cases per 100 000 persons, and cumulative incidence in 2021 was 1.2–1.8 cases per 100 000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and/or 2L+ MF‐related treatment was 4.0 cases per 100 000. Among these patients, 47.1%–53.7% required treatment for anemia, resulting in a period prevalence of 1.9–2.2 cases per 100 000 individuals.
Conclusion
The data reveal gaps in MF treatments and the need to improve patient quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GSK, Value, Evidence and Outcomes Europe, London, UK.
- GSK, Munich, Germany.
- GSK, Collegeville, Pennsylvania, USA.
- IPAM, Wismar, Germany.
- Ingress-Health HWM GmbH, a Cytel Company, Berlin, Germany.
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, Germany.
ORCID-Profile: Alexander Slowley
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Slowley, A., Weinmann, S., d'Estrube, T., Phiri, K., Karl, F. M., Gleißner, E., Mueller, S., Junker, S., & Göthert, J. R. (2024). Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment. European Journal of Haematology. https://doi.org/10.1111/ejh.14284
Vancouver
Slowley A, Weinmann S, d'Estrube T, Phiri K, Karl FM, Gleißner E, et al. Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment. European Journal of Haematology. 2024. doi:10.1111/ejh.14284
BibTeX
@article{Slowley2024,
author = {Slowley, Alexander and Weinmann, Sofie and d'Estrube, Tim and Phiri, Kelesitse and Karl, Florian M and Gleißner, Erika and Mueller, Sabrina and Junker, Sophia and Göthert, Joachim R},
title = {Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14284}
}
EUVIMED